These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 28158234)

  • 21. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
    Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
    Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.
    Christenson JL; Denny EC; Kane SE
    Oncotarget; 2015 Oct; 6(32):33134-45. PubMed ID: 26430732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
    Nahta R; Yuan LX; Du Y; Esteva FJ
    Mol Cancer Ther; 2007 Feb; 6(2):667-74. PubMed ID: 17308062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
    Gu S; Hu Z; Ngamcherdtrakul W; Castro DJ; Morry J; Reda MM; Gray JW; Yantasee W
    Oncotarget; 2016 Mar; 7(12):14727-41. PubMed ID: 26894975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
    Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
    Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
    Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J
    BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer.
    Alexander PB; Chen R; Gong C; Yuan L; Jasper JS; Ding Y; Markowitz GJ; Yang P; Xu X; McDonnell DP; Song E; Wang XF
    J Biol Chem; 2017 Jan; 292(2):748-759. PubMed ID: 27903634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
    Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
    Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
    Sato Y; Yashiro M; Takakura N
    Cancer Sci; 2013 Dec; 104(12):1618-25. PubMed ID: 24112719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
    Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
    Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
    Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
    PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
    Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
    Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
    Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
    Sethunath V; Hu H; De Angelis C; Veeraraghavan J; Qin L; Wang N; Simon LM; Wang T; Fu X; Nardone A; Pereira R; Nanda S; Griffith OL; Tsimelzon A; Shaw C; Chamness GC; Reis-Filho JS; Weigelt B; Heiser LM; Hilsenbeck SG; Huang S; Rimawi MF; Gray JW; Osborne CK; Schiff R
    Mol Cancer Res; 2019 Nov; 17(11):2318-2330. PubMed ID: 31420371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.